PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer's disease (AD) and to date has been assumed to bind with high affinity and specificity to the amyloid structures associated with classical plaques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investigated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during in vivo imaging scans. Using a combination of autoradiography and histochemical techniques, we demonstrate that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy (CAA). The interaction of PIB with CAA was not fully displaceable and this may be linked to the apolipoprotein E-epsilon4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was markedly lower than that associated with the amyloid-beta (Abeta) pathology. The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Abeta-peptide related cerebral amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Images of adjacent MFG sections from two Category A pathology cases (A1in A^C ; A2 in D^G ), showing correspondence of [3H]-PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Higher power representative images of boxed area from case A2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). Scale bar 1mm.](https://figures.cochat.ai/paper-figures/53cf42bb40d34aaf9b53cf4f09ffbcbc/pib-is-a-non-specific-imaging-marker-of-amyloid-beta-a-peptide-related-cerebral-figure-1.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pittsburgh Compound B retention is not specific for CAA as opposed to Alzheimer disease, because the compound binds to both vascular and parenchymal amyloid158; however, the 2 pathologies may be distinguishable in part by the relative occipital predominance of labeling in CAA.156,157”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 5×
“…vivo observations with data from both the large number of antecedent postmortem studies detailing the regional, microscopic spread of AD pathology (Braak and Braak, 1991a; Berg et al., 1998; Price and Morris, 1999) and the relatively sparse literature characterizing the interaction of imaging…”
BackgroundMethodInfluentialMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 5×
“Additionally, an inverse correlation of PIB retention with the pattern of decreased regional cerebral glucose metabolism rate (rCMRglc) has been observed (Klunk et al., 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).”
BackgroundResultInfluentialConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 3×
“…retention of [11C]-PIB in brain regions not normally associated with a high CP load such as the striatum and frontal cortex (Klunk et al., 2004; Nordberg, 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007) cannot readily be explained by the reported specificity of PIB for CPs.”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 979 · cited 1×
“…protocols used in this study differ significantly from the previous studies investigating the interaction of PIB with human brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004; Bacskai et al., 2007) and that these may explain the novel findings associated with the current study.”
Alzheimer’s amyloid fibrils: structure and assembly
Serpell, L. C. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00029-6 · Cited by 959 · cited 1×
“Both Ab, which forms the fibrils variably associated with SPs (and cerebrovascular amyloid), and tau, which forms the paired helical and straight filaments associated with NFTs, are types of amyloid (Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).”
BackgroundAlzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 818 · cited 1×
“Secondly, the dichotomy of the ligand retention pattern into essentially ‘PIB-positive’ or ‘PIB-negative’ is at odds both with the central role of the CP in disease progression (Selkoe and Schenk, 2003).”
BackgroundShoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S.-C., et al. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00004 · Cited by 770 · cited 2×
“, 2004) and [18F]-FDDNP (Shoghi-Jadid et al., 2002; Small et al., 2006) are currently undergoing evaluation studies in dementia populations; understanding their molecular binding profile using analogous experimental procedures will be critical in evaluating their potential as imaging biomarkers.”
BackgroundMethodPET of Brain Amyloid and Tau in Mild Cognitive Impairment
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054625 · Cited by 738 · cited 2×
“, 2004) and [18F]-FDDNP (Shoghi-Jadid et al., 2002; Small et al., 2006) are currently undergoing evaluation studies in dementia populations; understanding their molecular binding profile using analogous experimental procedures will be critical in evaluating their potential as imaging biomarkers.”
BackgroundMethodBerg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657 · cited 9×
“, 1990) and that CPs are not a dominant pathological feature of the frontal cortex during the early stages of AD (Mochizuki et al., 1996; Berg et al., 1998; Price and Morris, 1999).”
BackgroundInfluentialTwo-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., & Nordberg, A. (2006) · Brain · doi:10.1093/brain/awl178 · Cited by 617 · cited 6×
“Additionally, an inverse correlation of PIB retention with the pattern of decreased regional cerebral glucose metabolism rate (rCMRglc) has been observed (Klunk et al., 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).”
BackgroundMethodResultInfluentialDemonstration of amyloid deposits and neurofibrillary changes in whole brain sections
Braak, H., & Braak, E. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00661.x · Cited by 598 · cited 5×
“…vivo observations with data from both the large number of antecedent postmortem studies detailing the regional, microscopic spread of AD pathology (Braak and Braak, 1991a; Berg et al., 1998; Price and Morris, 1999) and the relatively sparse literature characterizing the interaction of imaging…”
BackgroundMethodInfluentialRegional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading
BRUN, A., & ENGLUND, E. (1981) · Histopathology · doi:10.1111/j.1365-2559.1981.tb01818.x · Cited by 561
Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518
PET imaging of amyloid in Alzheimer's disease
Nordberg, A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00853-1 · Cited by 464 · cited 4×
“First, the high retention of [11C]-PIB in brain regions not normally associated with a high CP load such as the striatum and frontal cortex (Klunk et al., 2004; Nordberg, 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007) cannot readily be explained by the reported specificity of PIB for CPs.”
BackgroundInfluentialNeuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460 · cited 1×
“However, the findings associated with this latter observation are not universal (Braak and Braak, 1991a; Markesbery et al., 2006).”
Background11 C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration
Rabinovici, G. D., Furst, A. J., O'Neil, J. P., Racine, C. A., Mormino, E. C., Baker, S. L., Chetty, S., Patel, P., Pagliaro, T. A., Klunk, W. E., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000259035.98480.ed · Cited by 410 · cited 3×
“The current study clearly supports the continued application of amyloid imaging as another clinical tool to identify and stratify dementias based on their cortical Ab load (Rowe et al., 2007; Rabinovici et al., 2007).”
BackgroundResultSanan, D. A., Weisgraber, K. H., Russell, S. J., Mahley, R. W., Huang, D., Saunders, A., Schmechel, D., Wisniewski, T., Frangione, B., & Roses, A. D. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117407 · Cited by 404 · cited 2×
“ApoE-e4 is linked both with CAA severity (Alonzo et al., 1998; Chalmers et al., 2003) and conformation changes to amyloid structure (Sanan et al., 1994), and these factors combined with biochemical differences in the Ab pools may account for the occurrence of the CAA-NDB.”
BackgroundKlunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., Debnath, M. L., Holt, D. P., Huang, G.-F., Shao, L., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2990-05.2005 · Cited by 377 · cited 1×
“Although, in vitro data indicates that the interaction of PIB with fibrils formed from either Ab 1-40 or Ab 1-42 is more or less identical (Klunk et al., 2005) this does not rule the possibility that post-translation modifications may selectivity alter the interaction of PIB with one pool.”
BackgroundMolecular Imaging With Pittsburgh Compound B Confirmed at Autopsy: A Case Report
Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., Irizarry, M. C., Klunk, W. E., Mathis, C. A., DeKosky, S. T., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.431 · Cited by 341 · cited 6×
“…protocols used in this study differ significantly from the previous studies investigating the interaction of PIB with human brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004; Bacskai et al., 2007) and that these may explain the novel findings associated with the current study.”
BackgroundResultInfluentialThe human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases
Braak, H., & Braak, E. (1992) · Neuroscience Research · doi:10.1016/0168-0102(92)90014-4 · Cited by 339 · cited 4×
“appears to be particularly susceptible to the formation of NFTs (Braak and Braak, 1992) and the cases associated with this category were pre-selected for their absence of Ab pathology.”
BackgroundInfluentialDifferences in neuropathologic characteristics across the Lewy body dementia spectrum
Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., Perry, E., & Aarsland, D. (2006) · Neurology · doi:10.1212/01.wnl.0000249130.63615.cc · Cited by 335 · cited 1×
“The deposition of Ab lesions is a common neuropathological finding in a number of conditions other than AD such as vascular dementia (Alonzo et al., 1998) and DLB (Tsuboi et al., 2005; Ballard et al., 2006).”
BackgroundIn-Vivo Imaging of Alzheimer Disease -Amyloid With [11C]SB-13 PET
Verhoeff, N. P. L. G. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.6.584 · Cited by 317 · cited 4×
“Alternative amyloid targeting ligands such as [11C]-SB13 (Verhoeff et al., 2004) and [18F]-FDDNP (Shoghi-Jadid et al.”
BackgroundMethodResultInfluentialKlunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., Shao, L., Hamilton, R. L., Ikonomovic, M. D., DeKosky, S. T., & Mathis, C. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02086.2003 · Cited by 309 · cited 2×
“…protocols used in this study differ significantly from the previous studies investigating the interaction of PIB with human brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004; Bacskai et al., 2007) and that these may explain the novel findings associated with the current study.”
MethodBerriman, J., Serpell, L. C., Oberg, K. A., Fink, A. L., Goedert, M., & Crowther, R. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530287100 · Cited by 288 · cited 1×
“Both Ab, which forms the fibrils variably associated with SPs (and cerebrovascular amyloid), and tau, which forms the paired helical and straight filaments associated with NFTs, are types of amyloid (Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).”
BackgroundBouras, C., Hof, P. R., Giannakopoulos, P., Michel, J.-P., & Morrison, J. H. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.2.138 · Cited by 280 · cited 2×
“…(e.g. the striatum) and the lack of increase in PIB binding associated with clinical disease progression may both be a consequence of PIB binding to DPs. Histopathological studies indicate that plaque load, a measure of both DPs and CPs, may be high in nondemented individuals (Bouras et al., 1994).”
BackgroundImaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain
Mathis, C., Wang, Y., & Klunk, W. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384772 · Cited by 243 · cited 6×
“…the use of autoradiography rather than fluorescence techniques permitted the use of concentrations (i.e. low nM range) relevant to in vivo imaging studies (Mathis et al., 2004; Rowe et al., 2007), with a detection method insensitive to potential tissue quenching and auto-fluorescence artefacts.”
BackgroundMethodInfluentialSporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 242 · cited 4×
“CAA is biochemically different to parenchymal SPs in that it is formed primarily from Ab 1-40 fibrils, although this varies with neuroanatomical location (Attems, 2005).”
BackgroundInfluentialSpectrum of morphological appearance of amyloid deposits in Alzheimer's disease
Wisniewski, H. M., Bancher, C., Barcikowska, M., Wen, G. Y., & Currie, J. (1989) · Acta Neuropathologica · doi:10.1007/bf00688170 · Cited by 221 · cited 2×
“For example studies have demonstrated that the vast majority of plaques in the striatum are of a diffuse plaque (DP) type (Wisniewski et al., 1989; Suenaga et al., 1990) and that CPs are not a dominant pathological feature of the frontal cortex during the early stages of AD (Mochizuki et al., 1996;…”
BackgroundLockhart, A., Ye, L., Judd, D. B., Merritt, A. T., Lowe, P. N., Morgenstern, J. L., Hong, G., Gee, A. D., & Brown, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412056200 · Cited by 213 · cited 1×
“The ability of [3H]-PIB to label DPs more intensely than Thioflavin S probably reflects the >100-fold higher affinity of radioligand for Ab fibrils relative to the dye (Lockhart et al., 2004).”
BackgroundSelf-citationBarghorn, S., Davies, P., & Mandelkow, E. (2004) · Biochemistry · doi:10.1021/bi0357006 · Cited by 209 · cited 1×
“Both Ab, which forms the fibrils variably associated with SPs (and cerebrovascular amyloid), and tau, which forms the paired helical and straight filaments associated with NFTs, are types of amyloid (Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).”
BackgroundMemory complaints are related to Alzheimer disease pathology in older persons
Barnes, L. L., Schneider, J. A., Boyle, P. A., Bienias, J. L., & Bennett, D. A. (2006) · Neurology · doi:10.1212/01.wnl.0000242734.16663.09 · Cited by 193 · cited 2×
“As no longitudinal PIB-PET data is available from these cognitively normal subjects, it is currently unclear whether these findings reflect the molecular development of prodomal AD (Barnes et al., 2006) or are consistent normal ageing.”
BackgroundArcher, H. A., Edison, P., Brooks, D. J., Barnes, J., Frost, C., Yeatman, T., Fox, N. C., & Rossor, M. N. (2006) · Annals of Neurology · doi:10.1002/ana.20889 · Cited by 179 · cited 2×
“In support of this premise a series of reports have demonstrated the increased, region specific, retention of [11C]-PIB in clinically diagnosed AD patients compared with non-demented control groups (Klunk et al., 2004; Verhoeff et al., 2004; Archer et al., 2006; Engler et al., 2006; Fagan et al., 2006; Edison et al.,…”
BackgroundResultDementia with Lewy bodies and Parkinson's disease with dementia: Are they different?
Tsuboi, Y., & Dickson, D. W. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.10.014 · Cited by 172
Chalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156 · cited 2×
“ApoE-e4 is linked both with CAA severity (Alonzo et al., 1998; Chalmers et al., 2003) and conformation changes to amyloid structure (Sanan et al., 1994), and these factors combined with biochemical differences in the Ab pools may account for the occurrence of the CAA-NDB.”
BackgroundProgression of Cerebral Amyloid Angiopathy: Accumulation of Amyloid-ß40 in Affected Vessels
Alonzo, N. C., Hyman, B. T., Rebeck, G. W., & Greenberg, S. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199804000-00008 · Cited by 146 · cited 4×
“The deposition of Ab lesions is a common neuropathological finding in a number of conditions other than AD such as vascular dementia (Alonzo et al., 1998) and DLB (Tsuboi et al.”
BackgroundInfluentialNeuropathology of Alzheimer's Disease
Mott, R. T., & Hulette, C. M. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.003 · Cited by 87
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Klunk, W. E., Mathis, C. A., Price, J. C., Lopresti, B. J., & DeKosky, S. T. (2006) · Brain · doi:10.1093/brain/awl281 · Cited by 87
Dickson, D. W. (2005) · Acta Neuropathologica · doi:10.1007/s00401-004-0950-z · Cited by 80 · cited 7×
“Immunohistochemical staining for A peptide using 6E10 The anti-Ab monoclonal antibody 6E10 is considered a sensitive marker for CPs and CAA, but may stain diffuse deposits less intensely (Dickson, 2005).”
BackgroundMethodInfluentialSuenaga, T., Hirano, A., Llena, J. F., Yen, S. H., & Dickson, D. W. (1990) · Acta Neuropathologica · doi:10.1007/bf00294646 · Cited by 79 · cited 2×
“For example studies have demonstrated that the vast majority of plaques in the striatum are of a diffuse plaque (DP) type (Wisniewski et al., 1989; Suenaga et al., 1990) and that CPs are not a dominant pathological feature of the frontal cortex during the early stages of AD (Mochizuki et al., 1996;…”
BackgroundShoghi-Jadid, K. (2002) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.10.1.24 · Cited by 65
Imaging Alzheimer's disease pathology: one target, many ligands
Lockhart, A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.008 · Cited by 61 · cited 4×
“, 1998; Price and Morris, 1999) and the relatively sparse literature characterizing the interaction of imaging probes with amyloid lesions (Lockhart, 2006) highlights a number of important discrepancies.”
BackgroundInfluentialSelf-citationPangalos, M. N., Jacobsen, S. J., & Reinhart, P. H. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330553 · Cited by 52 · cited 2×
“Although, the current study does not directly address the ability of PIB to act as a pharmacodynamic marker, for drugs targeting Ab metabolism (Pangalos et al., 2005), the data suggests that any change in the cortical uptake of the ligand cannot be ascribed to the appearance or disappearance of a particular Ab lesion…”
BackgroundMochizuki, A., Peterson, J. W., Mufson, E. J., & Trapp, B. D. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0181 · Cited by 43 · cited 2×
“…vast majority of plaques in the striatum are of a diffuse plaque (DP) type (Wisniewski et al., 1989; Suenaga et al., 1990) and that CPs are not a dominant pathological feature of the frontal cortex during the early stages of AD (Mochizuki et al., 1996; Berg et al., 1998; Price and Morris, 1999).”
BackgroundAmyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study
Verma, A. (2008) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)79016-1 · Cited by 35 · cited 5×
“Additionally, an inverse correlation of PIB retention with the pattern of decreased regional cerebral glucose metabolism rate (rCMRglc) has been observed (Klunk et al., 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).”
BackgroundResultInfluentialNeuropathologic Substrate of Mild Cognitive Impairment
Verma, A. M. (2007) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70062-0 · Cited by 29
Subpial β/A4 amyloid deposition occurs between astroglial processes in Alzheimer-type dementia
Yamaguchi, H., Nakazato, Y., Yamazaki, T., Shoji, M., Kawarabayashi, T., & Hirai, S. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90934-l · Cited by 20 · cited 1×
“The Ab deposits in subpial lesions have been demonstrated to be diffuse, with only small amounts of amyloid fibrils present (Yamaguchi et al., 1991).”
BackgroundAmyloid, hypometabolism, and cognition in Alzheimer disease - An [11C]PIB and [18F]FDG PET study
Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y., Hotton, G. R., Cutler, D., Fox, N. C., Kennedy, A. M., et al. (2007) · UCL Discovery (University College London) · Cited by 17
Shift from fibrillar to nonfibrillar Aß deposits in the neocortex of subjects with Alzheimer disease
Węgiel, J., Bobinski, M., Tarnawski, M. J., Dziewíatkowski, J., Popovitch, E. R., Bobinski, M., Lach, B., Reisberg, ., Miller, D. C., Santi, S. D., et al. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3108 · Cited by 14 · cited 1×
“While CPs may increase with further overt disease progression, degradation and loss of CPs may also occur as late clinical stages are reached (Brun et al., 1981, 1985; Wegiel et al., 2001).”
BackgroundThe structural development of Alzheimer's disease.
Brun, A. (1985) · PubMed · Cited by 10
Price (1999) · doi:10.1002/1531-8249(199903)45:3
Research works printed but not linked: 3
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothia- zoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
- Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
- Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-12.
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
“…compound B (PIB) primarily measure brain amyloid plaque load (Klunk et al ., 2004; Rowe et al ., 2007; Drzezga et al ., 2008; Ikonomovic et al ., 2008; Leinonen et al ., 2008) but also localize in cerebral vascular amyloid (Bacskai et al ., 2007; Johnson et al ., 2007; Lockhart et al ., 2007).”
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
“deposits indeed bind PIB although not specifically [207].”
BackgroundAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Metadata
- Authors
- Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- University Hospital of Basel (CH)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 130
- Issue
- 10
- Pages
- 2607-2615
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2031309116
- Cited by
- 302
- References
- 55
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 15 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 35
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research (211002, P30 AG19610)
- GlaxoSmithKline
- Arizona Department of Health Services (P30 AG19610, 211002, Contract 211002)
- Arizona Biomedical Research Commission (P30 AG19610, contract 0011, 211002)
- National Institute on Aging (211002, P30-AG-19610, AG-19610, P30AG019610)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- Pittsburgh compound B, [11C]PIB, amyloid-beta, cerebral amyloidosis, Alzheimer's disease, diffuse plaques, neurofibrillary tangles, APOE ε4, autoradiography, amyloid imaging
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Humans, Thiazoles, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.